C81.26 Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes

Name of the Condition

• Mixed Cellularity Hodgkin Lymphoma, Intrapelvic Lymph Nodes (ICD-10: C81.26)

Summary

Mixed cellularity Hodgkin lymphoma is a subtype of Hodgkin lymphoma characterized by a heterogeneous mix of cell types within affected lymph nodes. It is one of the classical Hodgkin lymphoma subtypes, distinguished by the presence of Reed-Sternberg cells and a variable inflammatory background. This subtype typically presents with widespread lymph node involvement and may affect other lymphoid tissues or organs. The "intrapelvic lymph nodes" designation specifies the anatomical location of the lymphoma.

Causes

The exact cause of mixed cellularity Hodgkin lymphoma is not fully understood, but it is associated with genetic mutations and immune system dysregulation. Epstein-Barr virus (EBV) infection is frequently linked to this subtype, suggesting a potential role in its development. Other contributing factors may include genetic predisposition and environmental exposures, though specific triggers remain under investigation.

Risk Factors

• Age: Most common in adults, with a peak incidence in the 30-50 age range.
• Gender: Slightly more prevalent in males.
• Epstein-Barr virus infection: Prior exposure increases risk.
• Immune system suppression: Conditions like HIV/AIDS or immunosuppressive therapy may elevate susceptibility.
• Family history: A first-degree relative with lymphoma may increase risk.

Symptoms

• Painless swelling of lymph nodes in the pelvic region
• Unexplained weight loss
• Fever
• Night sweats
• Fatigue
• Pruritus (itching)

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT or PET scans), and biopsy of the affected lymph node. Histopathological examination confirms the presence of Reed-Sternberg cells and the mixed cellularity pattern. Staging is performed to determine the extent of disease, which guides treatment planning.

Treatment Options

Treatment typically includes chemotherapy, often with regimens like ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). Radiation therapy may be used for localized disease. Stem cell transplantation is considered for relapsed or refractory cases. Treatment plans are individualized based on disease stage and patient factors.

Prognosis and Follow-Up

Prognosis varies depending on disease stage, response to treatment, and patient characteristics. Early-stage disease generally has a favorable prognosis with standard therapy. Regular follow-up is essential to monitor for recurrence, manage long-term effects of treatment, and address potential complications.

Complications

• Recurrence of lymphoma
• Treatment-related toxicities (e.g., cardiopulmonary effects from chemotherapy or radiation)
• Secondary malignancies
• Infection risk due to immunosuppression
• Lymphedema (swelling from lymph node removal or damage)

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular exercise.
• Avoid known environmental risk factors (e.g., excessive radiation exposure).
• Practice good hygiene to reduce infection risk, especially if immunosuppressed.
• Stay up-to-date with vaccinations as recommended by healthcare providers.

When to Seek Professional Help

Seek medical attention if you experience persistent pelvic lymph node swelling, unexplained weight loss, fever, night sweats, or fatigue. Early evaluation is critical for timely diagnosis and treatment.

Tips for Medical Coders

Document the specific anatomical location (intrapelvic lymph nodes) to support code assignment. Ensure clinical documentation aligns with the ICD-10-CM code C81.26, specifying the site to avoid ambiguity. Verify that the diagnosis is confirmed by histopathological findings and staging information is available for accurate coding.